Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Members of management will present on March 4, 2026, at 10:30 a.m. EST.A live webcast of the Company's prese ...

Core Insights - Cardiol Therapeutics Inc. has published results from its Phase II ARCHER study, demonstrating the efficacy of its lead drug candidate, CardiolRx™, in treating acute myocarditis, which is a significant cause of heart failure in young adults [1][2][3] Company Overview - Cardiol Therapeutics Inc. is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate being CardiolRx™ [6][9] - The company is also developing CRD-38, a novel subcutaneously administered drug formulation aimed at treating inflammatory heart disease, including heart failure, which incurs healthcare costs exceeding US$30 billion annually in the U.S. [9] Study Findings - The Phase II ARCHER study involved 109 patients and showed that treatment with CardiolRx™ resulted in a significant reduction in left ventricular mass by 9.2 grams compared to placebo (p=0.0117), alongside decreased left atrial remodeling and favorable trends in myocardial inflammation markers [3][4] - The safety and tolerability of CardiolRx™ were confirmed in the study, indicating its potential to improve clinical outcomes in myocarditis patients [3] Ongoing Trials - The biological signals observed in the ARCHER study are relevant to Cardiol's ongoing pivotal Phase III MAVERIC trial, which focuses on recurrent pericarditis, an inflammatory disease of the pericardium [4][7] - The MAVERIC program includes the completed Phase II MAvERIC-Pilot study and the ongoing Phase III MAVERIC trial, with the U.S. FDA granting Orphan Drug Designation to CardiolRx™ for recurrent pericarditis [7] Management Commentary - The CEO of Cardiol Therapeutics emphasized that the publication of the ARCHER study results enhances confidence in the MAVERIC trial and highlights CardiolRx's impact on inflammatory heart disease [5]

Core Viewpoint - Cardiol Therapeutics Inc. has announced a private placement offering to raise gross proceeds of $13.5 million by selling 10,384,616 units at a price of $1.30 per unit, with an option for the underwriter to purchase an additional 10% of the units sold [1][4]. Group 1: Offering Details - The offering consists of units that include one Class A common share and one-half of a common share purchase warrant, with each warrant allowing the purchase of one common share at an exercise price of $1.75 for 24 months [2]. - The offering is scheduled to close on or about January 23, 2026, subject to necessary approvals, including TSX approval, and the negotiation of an underwriting agreement [4]. - A cash commission of 6% of the aggregate gross proceeds will be paid to the underwriter upon closing of the offering [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance the company's research and clinical development programs, as well as for general and administrative expenses and working capital [3]. Group 3: Company Overview - Cardiol Therapeutics is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting conditions like pericarditis and myocarditis [9][10]. - The company is also developing CRD-38, a novel drug formulation for treating inflammatory heart disease, which is a significant cause of death and hospitalization in developed countries [12].

Core Viewpoint - Cardiol Therapeutics Inc. has announced a private placement offering to raise gross proceeds of $13.5 million by selling 10,384,616 units at a price of $1.30 per unit, with an option for the underwriter to purchase an additional 10% of the units sold [1][4] Group 1: Offering Details - The offering consists of units that include one Class A common share and one-half of a common share purchase warrant, with each warrant allowing the purchase of one common share at an exercise price of $1.75 for 24 months [2] - The offering is scheduled to close on or about January 23, 2026, subject to necessary approvals, including from the TSX [4] - A cash commission of 6% of the aggregate gross proceeds will be paid to the underwriter upon closing [4] Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance research and clinical development programs, as well as for general administrative expenses and working capital [3] Group 3: Company Overview - Cardiol Therapeutics is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting conditions like pericarditis and myocarditis [9][10] - The company is also developing CRD-38, a novel drug formulation for inflammatory heart disease, which is a significant cause of death and hospitalization in developed countries [12]

Core Viewpoint - Cardiol Therapeutics has successfully completed a private placement offering, securing US$11 million in net proceeds to enhance its financial position and support the development of its heart failure drug, CRD-38, following promising results from its ARCHER trial [3][4]. Financing Details - The company completed an initial closing of US$10 million, with an additional US$1 million expected to close on October 20, 2025 [3]. - A total of 11 million units were sold at a price of US$1.00 per unit, with each unit consisting of one common share and one-half of a common share purchase warrant [4]. - The warrants allow the holder to acquire one additional common share at an exercise price of US$1.35 for 24 months, with an acceleration provision if the share price exceeds US$2.00 for five consecutive trading days [4]. Clinical Development - The funds will support operations into Q3 2027, enabling the advancement of the MAVERIC Phase III trial for CardiolRx™ and the development of the next-generation CRD-38 formulation [4][5]. - Topline results from the ARCHER trial indicated a significant reduction in left ventricular (LV) mass, marking a key clinical validation in treating inflammatory heart disease [4]. - The company aims to pursue an additional Orphan Drug Designation for CardiolRx™ in myocarditis, leveraging the ARCHER findings to target a broader heart failure market [4]. Market Context - Heart failure remains a significant health issue, with five-year mortality rates exceeding 50%, highlighting the clinical potential of Cardiol's therapies [4]. - The healthcare costs associated with heart failure in the U.S. exceed US$30 billion annually, indicating a substantial market opportunity for effective treatments [12].

Core Insights - Cardiol Therapeutics announced topline results from the Phase II ARCHER trial of CardiolRx™ in patients with acute myocarditis, showing a notable improvement in extracellular volume (ECV) compared to placebo [2][4] - The trial demonstrated safety and tolerability of CardiolRx™, supporting its advancement in clinical development for cardiomyopathies, heart failure, and myocarditis [2][5] Clinical Trial Results - The primary endpoints of the ARCHER trial were ECV and global longitudinal strain (GLS), with ECV showing significant improvement (p = 0.0538) after 12 weeks of treatment [2][4] - Improvements in ECV were associated with reductions in multiple cardiac magnetic resonance imaging (CMR) endpoints, including a significant reduction in left ventricular (LV) mass [4][5] - The trial enrolled 109 patients across multiple countries, including the United States, France, Brazil, and Israel [5][8] Company Overview - Cardiol Therapeutics is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate being CardiolRx™, a pharmaceutically manufactured cannabidiol oral solution [7][9] - The company has received FDA authorization for clinical studies evaluating CardiolRx™ in recurrent pericarditis and acute myocarditis, with ongoing Phase III trials [8][9] Industry Context - Acute myocarditis is a significant cause of heart failure and sudden cardiac death, particularly in individuals under 35 years of age, with no FDA-approved drug therapies currently available [6] - The healthcare costs associated with heart failure in the U.S. exceed $30 billion annually, highlighting the potential market for effective treatments [9]

Company Overview - Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease [4] - The company's lead drug candidate, CardiolRx™ (cannabidiol) oral solution, is in clinical development for treating heart disease and is recognized for inhibiting the inflammasome pathway, which is crucial in inflammation and fibrosis related to myocarditis, pericarditis, and heart failure [4] Clinical Development - Cardiol has received Investigational New Drug Application authorization from the US FDA to conduct clinical studies for CardiolRx™ in recurrent pericarditis and acute myocarditis [5] - The MAVERIC Program for recurrent pericarditis includes the completed Phase II MAvERIC-Pilot study and the ongoing Phase III MAVERIC trial [5] - The ongoing ARCHER trial is a Phase II study in acute myocarditis, a significant cause of heart failure and sudden cardiac death in young adults [5] Financial Context - Heart failure is a leading cause of death and hospitalization in developed countries, with associated healthcare costs in the US exceeding $30 billion annually [6] Upcoming Events - The company's virtual Annual General Meeting (AGM) is scheduled for May 28, 2025, at 4:30 p.m. EDT, and will be accessible via live audio webcast [2][3]